Atyr PHARMA (ATYR) Competitors

Ocular Therapeutix (NASDAQ:OCUL) and Atyr PHARMA (NASDAQ:ATYR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, community ranking, analyst recommendations, profitability and valuation.

Which has better earnings & valuation, OCUL or ATYR?

Atyr PHARMA has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Atyr PHARMA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$58.44M	19.01	-$80.74M	-$1.32	-5.35
Atyr PHARMA	$350K	1,050.45	-$50.39M	-$0.94	-4.66

Does the media refer more to OCUL or ATYR?

In the previous week, Atyr PHARMA had 13 more articles in the media than Ocular Therapeutix. MarketBeat recorded 14 mentions for Atyr PHARMA and 1 mentions for Ocular Therapeutix. Atyr PHARMA's average media sentiment score of 0.89 beat Ocular Therapeutix's score of 0.39 indicating that Atyr PHARMA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atyr PHARMA	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is OCUL or ATYR more profitable?

Atyr PHARMA has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -283.74%. Ocular Therapeutix's return on equity of -45.18% beat Atyr PHARMA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-283.74%	-45.18%	-30.87%
Atyr PHARMA	N/A	-79.44%	-59.16%

Does the MarketBeat Community favor OCUL or ATYR?

Ocular Therapeutix received 425 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 70.14% of users gave Ocular Therapeutix an outperform vote.

Company	Underperform	Outperform
Ocular Therapeutix	Outperform Votes 437 70.14%	Underperform Votes 186 29.86%
Atyr PHARMA	Outperform Votes 12 100.00%	Underperform Votes No Votes

Do analysts prefer OCUL or ATYR?

Ocular Therapeutix presently has a consensus price target of $17.00, suggesting a potential upside of 140.62%. Atyr PHARMA has a consensus price target of $18.60, suggesting a potential upside of 324.66%. Given Atyr PHARMA's stronger consensus rating and higher probable upside, analysts clearly believe Atyr PHARMA is more favorable than Ocular Therapeutix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Atyr PHARMA	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

Do insiders & institutionals have more ownership in OCUL or ATYR?

59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are held by institutional investors. 3.5% of Ocular Therapeutix shares are held by company insiders. Comparatively, 3.7% of Atyr PHARMA shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has more volatility & risk, OCUL or ATYR?

Ocular Therapeutix has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Comparatively, Atyr PHARMA has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.

Summary

Atyr PHARMA beats Ocular Therapeutix on 14 of the 19 factors compared between the two stocks.